Dr. Michael Eichberg is Senior Director of Strategic Alliances at Merck Research Laboratories, where he oversees research and development collaborations in multiple therapeutic areas. For ERVEBO (V920, rVSVΔG-ZEBOV-GP), a live, attenuated viral vaccine against the Ebola Zaire virus. he manages development relationships with the U.S. government and academic researchers. He is also involved with many of Merck’s other public-private partnerships for the development and discovery of innovative medicines. Prior to joining Merck, he was head of Alliance Management at Achaogen, Inc., a biopharmaceutical firm with extensive U.S. government collaborations focused on novel antibiotic development. He has also served as the Executive Director of the Center for Emerging and Neglected Diseases (CEND) at the University of California, Berkeley, an academic center dedicated to promoting awareness, education, and research in infectious diseases, particularly those affecting poorer populations around the world. He has served as a professional staff member in the U.S. House of Representatives and as a legislative liaison and policy analyst with the American Chemical Society. He received his Ph.D. in Chemistry from the University of California, Berkeley, and his B.A. from Cornell University.